Literature DB >> 17722965

Nitazoxanide: a review of its use in the treatment of gastrointestinal infections.

Vanessa R Anderson1, Monique P Curran.   

Abstract

Nitazoxanide (Alinia, Daxon, Dexidex, Paramix, Kidonax, Colufase, Annita) has in vitro activity against a variety of microorganisms, including a broad range of protozoa and helminths. Nitazoxanide is effective in the treatment of protozoal and helminthic infections, including Cryptosporidium parvum or Giardia lamblia, in immunocompetent adults and children, and is generally well tolerated. Nitazoxanide is a first-line choice for the treatment of illness caused by C. parvum or G. lamblia infection in immunocompetent adults and children, and is an option to be considered in the treatment of illnesses caused by other protozoa and/or helminths.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722965     DOI: 10.2165/00003495-200767130-00015

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  72 in total

1.  Nitazoxanide: an important advance in anti-parasitic therapy.

Authors:  A Clinton White
Journal:  Am J Trop Med Hyg       Date:  2003-04       Impact factor: 2.345

2.  In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms.

Authors:  L Dubreuil; I Houcke; Y Mouton; J F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells.

Authors:  G Gargala; A Delaunay; X Li; P Brasseur; L Favennec; J J Ballet
Journal:  J Antimicrob Chemother       Date:  2000-07       Impact factor: 5.790

4.  Giardia lamblia carriage in Israeli Bedouin infants: risk factors and consequences.

Authors:  D Fraser; N Bilenko; R J Deckelbaum; R Dagan; J El-On; L Naggan
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

5.  Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.

Authors:  Daniel M Musher; Nancy Logan; Vaibhav Mehendiratta; Nicolas A Melgarejo; Sagar Garud; Richard J Hamill
Journal:  J Antimicrob Chemother       Date:  2007-03-02       Impact factor: 5.790

Review 6.  Parasitic infections of the intestine.

Authors:  H Schuster; P L Chiodini
Journal:  Curr Opin Infect Dis       Date:  2001-10       Impact factor: 4.915

7.  Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model.

Authors:  Xunde Li; Philippe Brasseur; Patrice Agnamey; Denis Leméteil; Loïc Favennec; Jean-Jacques Ballet; Jean-François Rossignol
Journal:  Folia Parasitol (Praha)       Date:  2003-03       Impact factor: 2.122

8.  Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species.

Authors:  Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  Characterization of Giardia lamblia WB C6 clones resistant to nitazoxanide and to metronidazole.

Authors:  Joachim Müller; Maaike Sterk; Andrew Hemphill; Norbert Müller
Journal:  J Antimicrob Chemother       Date:  2007-06-08       Impact factor: 5.790

Review 10.  Nitazoxanide treatment for giardiasis and cryptosporidiosis in children.

Authors:  Jason M Bailey; John Erramouspe
Journal:  Ann Pharmacother       Date:  2004-02-27       Impact factor: 3.154

View more
  53 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

2.  Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Joseph Salamoun; Michelle Warthan; Paul S Hoffman; Timothy L Macdonald
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

Review 3.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

4.  Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer.

Authors:  Yi Qu; Jan Roger Olsen; Xing Yuan; Phil F Cheng; Mitchell P Levesque; Karl A Brokstad; Paul S Hoffman; Anne Margrete Oyan; Weidong Zhang; Karl-Henning Kalland; Xisong Ke
Journal:  Nat Chem Biol       Date:  2017-10-30       Impact factor: 15.040

5.  Characterization of a melamino nitroheterocycle as a potential lead for the treatment of human african trypanosomiasis.

Authors:  Federica Giordani; Annamaria Buschini; Alessandro Baliani; Marcel Kaiser; Reto Brun; Michael P Barrett; Claudia Pellacani; Paola Poli; Ian H Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

Review 6.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 7.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

8.  Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways.

Authors:  Kent Miner; Katja Labitzke; Benxian Liu; Paul Wang; Kathryn Henckels; Kevin Gaida; Robin Elliott; Jian Jeffrey Chen; Longbin Liu; Anh Leith; Esther Trueblood; Kelly Hensley; Xing-Zhong Xia; Oliver Homann; Brian Bennett; Mike Fiorino; John Whoriskey; Gang Yu; Sabine Escobar; Min Wong; Teresa L Born; Alison Budelsky; Mike Comeau; Dirk Smith; Jonathan Phillips; James A Johnston; Joseph G McGivern; Kerstin Weikl; David Powers; Karl Kunzelmann; Deanna Mohn; Andreas Hochheimer; John K Sullivan
Journal:  Front Pharmacol       Date:  2019-02-14       Impact factor: 5.810

9.  Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Paul S Hoffman; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2010-05-18       Impact factor: 2.823

10.  Microbial adhesion of Cryptosporidium parvum: identification of a colostrum-derived inhibitory lipid.

Authors:  Joann Schmidt; Mark S Kuhlenschmidt
Journal:  Mol Biochem Parasitol       Date:  2008-07-15       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.